Staff Profile: Wenjuan Ye

Wenjuan Ye, M.B.

Research Scientist

Division of Preclinical Innovation
Biology (Contractor)

National Center for Advancing Translational Sciences

National Institutes of Health

Email Wenjuan Ye


Wenjuan Ye is a research scientist of biology on the thymine team within NCATS’ Division of Preclinical Innovation, where she develops and optimizes cell-based biochemical assays with small molecules identified in fully automated robotic screening. She evaluates new technologies, resulting in proposals for new screening strategies and novel assays formats; confirms assays; and determines EC50 specificity for primary samples.

Before joining NCATS in 2011, Ye previously worked as a lab associate at the Whitehead/MIT Center for Genome Research. Ye participated in the Human Genome Project to develop genetic mapping of the human and mouse genomes, using various molecular techniques and sequencing human genomic DNA. She also served as a senior research technician at Brigham and Women’s Hospital. She worked on g-secretase identification and purification in an Alzheimer’s disease study by characterizing proteins and analyzing protein function, substrate selectivity and regulation of g-secretase by small molecules.

Ye earned her Bachelor of Medicine from the First Medical School of Shanghai in China and received certification in laboratory technical skills from Boston University School of Medicine’s Cambridge Biomedical Careers Initiative.

Research Topics

As part of the team led by Marc Ferrer, Ph.D., Ye collaborated with several research groups to establish and optimize the assay model to search a small molecules library to find drug candidates for several medical problems. For example, the parathyroid hormone receptor type-1 (PTHR1) plays critical roles in maintaining blood calcium and phosphate levels, as well as in controlling bone remodeling. Although researchers have known for decades about the bone anabolic effect of intermittent treatment with PTH, the identified PTHR1 agonists provide promising candidates for further drug development for treating hypoparathyroidism and osteoporosis.